Department of Molecular Genetics, Oncode Institute, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, the Netherlands.
Department of Molecular Genetics, Oncode Institute, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, the Netherlands.
DNA Repair (Amst). 2019 May;77:87-95. doi: 10.1016/j.dnarep.2019.03.007. Epub 2019 Mar 15.
SWI/SNF complexes are among the most studied ATP-dependent chromatin remodeling complexes, mostly due to their critical role in coordinating chromatin architecture and gene expression. Mutations in genes encoding SWI/SNF subunits are frequently observed in a large variety of human cancers, suggesting that one or more of the multiple SWI/SNF functions protect against tumorigenesis. Chromatin remodeling is an integral component of the DNA damage response (DDR), which safeguards against DNA damage-induced genome instability and tumorigenesis by removing DNA damage through interconnected DNA repair and signaling pathways. SWI/SNF has been implicated in facilitating repair of double-strand breaks, by non-homologous end-joining as well as homologous recombination, and repair of helix-distorting DNA damage by nucleotide excision repair. Here, we review current knowledge on SWI/SNF activity in the DDR and discuss the potential of exploiting DDR-related vulnerabilities due to SWI/SNF dysfunction for precision cancer therapy.
SWI/SNF 复合物是研究最多的 ATP 依赖的染色质重塑复合物之一,主要是因为它们在协调染色质结构和基因表达方面的关键作用。编码 SWI/SNF 亚基的基因突变经常在多种人类癌症中观察到,这表明 SWI/SNF 的多种功能之一或多种功能可以预防肿瘤发生。染色质重塑是 DNA 损伤反应 (DDR) 的一个组成部分,通过通过相互连接的 DNA 修复和信号通路去除 DNA 损伤,从而防止 DNA 损伤引起的基因组不稳定性和肿瘤发生。SWI/SNF 被认为有助于通过非同源末端连接以及同源重组修复双链断裂,并且通过核苷酸切除修复修复螺旋扭曲的 DNA 损伤。在这里,我们回顾了 SWI/SNF 在 DDR 中的活性的最新知识,并讨论了由于 SWI/SNF 功能障碍而利用 DDR 相关脆弱性进行精确癌症治疗的潜力。
DNA Repair (Amst). 2019-3-15
DNA Repair (Amst). 2020-9
Annu Rev Pathol. 2014-10-27
Cell Cycle. 2014
J Cell Mol Med. 2023-4
DNA Repair (Amst). 2009-1-1
Front Cell Dev Biol. 2022-12-20
Cells. 2025-6-5
Int J Oncol. 2025-4
Signal Transduct Target Ther. 2025-2-21
Neurooncol Adv. 2024-10-4
Cell Commun Signal. 2024-9-30
Cell Commun Signal. 2024-9-11